title: Kinetic and structural determinants for GABA-A receptor potentiation by neuroactive steroids.
abstract: Endogenous neurosteroids and synthetic neuroactive steroid analogs are among the most potent and efficacious potentiators of the mammalian GABA-A receptor. The compounds interact with one or more sites on the receptor leading to an increase in the channel open probability through a set of changes in the open and closed time distributions. The endogenous neurosteroid allopregnanolone potentiates the α1β2γ2L GABA-A receptor by enhancing the mean duration and prevalence of the longest-lived open time component and by reducing the prevalence of the longest-lived intracluster closed time component. Thus the channel mean open time is increased and the mean closed time duration is decreased, resulting in potentiation of channel function. Some of the other previously characterized neurosteroids and steroid analogs act through similar mechanisms while others affect a subset of these parameters. The steroids modulate the GABA-A receptor through interactions with the membrane-spanning region of the receptor. However, the number of binding sites that mediate the actions of steroids is unclear. We discuss data supporting the notions of a single site vs. multiple sites mediating the potentiating actions of steroids.
authors.affiliation: Departments of Anesthesiology (GA, ASE, JHS), Washington University School of Medicine, St. Louis, MO, USA. akk@wustl.edu
authors.forename: Gustav
authors.initials: G
authors.lastname: Akk
authors.forename: Douglas F
authors.initials: DF
authors.lastname: Covey
authors.forename: Alex S
authors.initials: AS
authors.lastname: Evers
authors.forename: Steven
authors.initials: S
authors.lastname: Mennerick
authors.forename: Charles F
authors.initials: CF
authors.lastname: Zorumski
authors.forename: Joe Henry
authors.initials: JH
authors.lastname: Steinbach
references.citation: Eur J Neurosci. 2006 Oct;24(7):1955-66
references.pmid: 17040476
references.citation: Br J Pharmacol. 2009 Nov;158(5):1322-9
references.pmid: 19702782
references.citation: Science. 1986 May 23;232(4753):1004-7
references.pmid: 2422758
references.citation: J Neurosci. 2003 Nov 5;23(31):10013-20
references.pmid: 14602815
references.citation: Ann N Y Acad Sci. 2006 Nov;1088:139-52
references.pmid: 17192562
references.citation: J Physiol. 1997 Dec 1;505 ( Pt 2):283-97
references.pmid: 9423172
references.citation: Mol Neurobiol. 2008 Apr-Jun;37(2-3):116-25
references.pmid: 18521763
references.citation: Mol Pharmacol. 2008 Sep;74(3):614-27
references.pmid: 18544665
references.citation: Br J Pharmacol. 2008 Mar;153(5):1062-71
references.pmid: 18204487
references.citation: Br J Pharmacol. 2007 Jan;150(2):164-75
references.pmid: 17160009
references.citation: Mol Pharmacol. 2007 Feb;71(2):461-72
references.pmid: 17105870
references.citation: J Physiol. 2007 Nov 1;584(Pt 3):789-800
references.pmid: 17761771
references.citation: J Physiol. 2003 Feb 1;546(Pt 3):641-6
references.pmid: 12562992
references.citation: Trends Pharmacol Sci. 1999 Mar;20(3):107-12
references.pmid: 10203866
references.citation: Mol Pharmacol. 2006 Jun;69(6):2015-26
references.pmid: 16554408
references.citation: J Med Chem. 2008 Mar 13;51(5):1309-18
references.pmid: 18275132
references.citation: Recent Prog Horm Res. 1997;52:1-32
references.pmid: 9238846
references.citation: Channels (Austin). 2007 Jul-Aug;1(4):238-45
references.pmid: 18708751
references.citation: Brain Res Brain Res Rev. 2001 Nov;37(1-3):133-40
references.pmid: 11744081
references.citation: J Med Chem. 2007 Nov 29;50(24):6048-58
references.pmid: 17963371
references.citation: Endocrinology. 1999 Aug;140(8):3843-52
references.pmid: 10433246
references.citation: Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14602-7
references.pmid: 16984997
references.citation: J Neurosci. 2005 Dec 14;25(50):11605-13
references.pmid: 16354918
references.citation: Mol Pharmacol. 2009 Jun;75(6):1400-11
references.pmid: 19289569
references.citation: J Neurophysiol. 2009 Aug;102(2):1254-64
references.pmid: 19553485
references.citation: Front Neuroendocrinol. 2000 Jan;21(1):1-56
references.pmid: 10662535
references.citation: Neuropharmacology. 2009 Jan;56(1):149-54
references.pmid: 18762201
references.citation: Eur J Med Chem. 2008 Jan;43(1):107-13
references.pmid: 17434649
references.citation: Neuroreport. 1998 Feb 16;9(3):379-83
references.pmid: 9512375
references.citation: Mol Pharmacol. 2009 Apr;75(4):973-81
references.pmid: 19176850
references.citation: Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4711-6
references.pmid: 16537405
references.citation: Brain Res. 1993 Dec 3;629(2):283-92
references.pmid: 8111631
references.citation: Mol Pharmacol. 1991 Sep;40(3):333-6
references.pmid: 1654510
references.citation: J Physiol. 2004 Apr 15;556(Pt 2):387-99
references.pmid: 14966300
references.citation: J Mol Neurosci. 2006;28(1):33-51
references.pmid: 16632874
references.citation: J Physiol. 2001 Dec 15;537(Pt 3):715-33
references.pmid: 11744750
references.citation: Nature. 2006 Nov 23;444(7118):486-9
references.pmid: 17108970
references.citation: Pharm Res. 1990 Aug;7(8):869-73
references.pmid: 2235884
references.citation: J Physiol. 2004 Jul 1;558(Pt 1):59-74
references.pmid: 15146041
references.citation: Pharmacol Ther. 2007 Oct;116(1):1-6
references.pmid: 17531324
references.citation: Mol Pharmacol. 2007 Jun;71(6):1582-90
references.pmid: 17341652